Microbiome company Finch raises $53M ahead of anti-infective readout

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Aug 23, 2019 at 10:12 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Finch's series C round is designed to carry the microbiome company through what could be a pivotal data readout next year in Clostridium difficile infection, while also allowing it to continue building on a pair of platforms that deliver bacterial cocktails to the gut.

    article source